Literature DB >> 19691688

The burden of the nonmedical use of prescription opioid analgesics.

Aaron M Gilson1, Paul G Kreis.   

Abstract

An increase in the prescribing of opioids over the past several years often has been perceived as the primary reason for the increase in the nonmedical use of prescription opioids. Determining the prevalence of this illicit use has been difficult, because of varied methodologies and terminologies that are used to estimate the number of people directly contributing to or affected by this burden. Despite these discrepancies, the findings from several nationally recognized surveys have demonstrated that the prevalence of nonmedical prescription opioid use is indeed significant and has been increasing in recent years. The considerable burden on society imposed by misuse and abuse of these drugs is largely due to the monetary costs associated with nonmedical use (e.g., strategies implemented to prevent or deter abuse, treatment programs for misusers, etc.), decreased economic productivity, and the indirect effect on access to appropriate health care. However, using various nonpharmacologic and pharmacologic approaches to treat patients who use prescription opioids illicitly can decrease its overall prevalence and associated impact, with the development of novel opioid formulations designed to reduce nonmedical use providing valuable clinical tools as part of an overall risk management program. In addition, prescription monitoring programs are a prevalent drug control system designed to identify and address abuse and diversion of prescription medications, including opioids. Such resources, along with an accurate understanding of the problem, extend greater hope that the public health challenge of nonmedical prescription opioid use can be effectively mitigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19691688     DOI: 10.1111/j.1526-4637.2009.00668.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  27 in total

1.  The effect of an educational intervention on meperidine use in Nova Scotia, Canada: a time series analysis.

Authors:  Judith E Fisher; Ying Zhang; Ingrid Sketris; Grace Johnston; Fred Burge
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-11-14       Impact factor: 2.890

Review 2.  Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Carmen Walter; Claudia Knothe; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 4.  [Chronic non-cancer-related pain. Long-term treatment with rapid-release and short-acting opioids in the context of misuse and dependency].

Authors:  R Scharnagel; U Kaiser; A Schütze; R Heineck; G Gossrau; R Sabatowski
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

Review 5.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

6.  Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes.

Authors:  Aaron M Gilson; Scott M Fishman; Barth L Wilsey; Carlos Casamalhuapa; Hassan Baxi
Journal:  J Pain       Date:  2011-11-23       Impact factor: 5.820

7.  National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009.

Authors:  Susan Calcaterra; Jason Glanz; Ingrid A Binswanger
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

8.  Role of key informants and direct patient interviews in epidemiological studies of substance abuse.

Authors:  Theodore J Cicero; Matthew S Ellis; Alethea Paradis; Zachary Ortbal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-09       Impact factor: 2.890

Review 9.  A Systematic Review of Opioid and Benzodiazepine Misuse in Older Adults.

Authors:  Rachel D Maree; Zachary A Marcum; Ester Saghafi; Debra K Weiner; Jordan F Karp
Journal:  Am J Geriatr Psychiatry       Date:  2016-06-07       Impact factor: 4.105

10.  Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Authors:  Perrine Roux; Maria A Sullivan; Julien Cohen; Lionel Fugon; Jermaine D Jones; Suzanne K Vosburg; Ziva D Cooper; Jeanne M Manubay; Shanthi Mogali; Sandra D Comer
Journal:  Pain       Date:  2013-05-07       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.